T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3630-3634

  Yamada, Eio ^a   Nishikawa, Hiroshi ^a   Nomura, Nobuhiko ^a   Mitsuyama, Junichi ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GLUCOSE; GLYCEROL; MICAFUNGIN; T 2307; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; CARBON SOURCE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; FUNGAL STRAIN; FUNGUS GROWTH; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

EID: 77956097960     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00355-10     Document Type: Article

References (25)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. (Pubitemid 127774267)
2. Agrawal, D., T. F. Patterson, M. G. Rinaldi, and S. G. Revankar. 2007. Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. J. Med. Microbiol. 56:1003-1004.
3. Arthington-Skaggs, B. A., D. W. Warnock, and C. J. Morrison. 2000. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 44:2081-2085.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Coenye, T., M. De Vos, D. Vandenbosch, and H. Nelis. 2007. Factors influencing the trailing endpoint observed in Candida albicans susceptibility testing using the CLSI procedure. Clin. Microbiol. Infect. 14:495-497.
6. Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C. Knapp, N. Holliday, and S. B. Killian. 2004. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721.
7. Ikeda, F., Y. Wakai, S. S. Matsumoto, K. Maki, E. Watabe, S. Tawara, T. Goto, Y. Watanabe, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44:614-618.
8. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
9. Lanteri, C. A., B. L. Trumpower, R. R. Tidwell, and S. R. Meshnick. 2004. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48:3968-3974.
10. Lee, M. K., L. E. Williams, D. W. Warnock, and B. A. Arthington-Skaggs. 2004. Drug resistance genes and trailing growth in Candida albicans isolates. J. Antimicrob. Chemother. 53:217-224.
11. Ludewig, G., J. M. Williams, Y. Li, and C. Staben. 1994. Effects of pentamidine isethionate on Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 38:1123-1128.
12. Marr, K. A., T. R. Rustad, J. H. Rex, and T. C. White. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob. Agents Chemother. 43:1383-1386.
13. Mitsuyama, J., N. Nomura, K. Hashimoto, E. Yamada, H. Nishikawa, M. Kaeriyama, A. Kimura, Y. Todo, and H. Narita. 2008. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob. Agents Chemother. 52:1318-1324.
14. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, and S. A. Messer. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 36:1886-1889.
15. Pfaller, M. A., C. Grant, V. Morthland, and J. Rhine-Chalberg. 1994. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J. Clin. Microbiol. 32:506-509.
16. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1998. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J. Clin. Microbiol. 36:153-156.
17. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel- Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
18. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. N. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
19. Rodriguez-Tudela, J. L., and J. V. Martinez-Suarez. 1994. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob. Agents Chemother. 38:45-48.
20. Rybak, B. 1968. Regulation of glycemia, p. 467-473. Principles of zoophysiology, vol. 1. Pergamon Press, London, United Kingdom.
21. Sanglard, D., F. Ischer, O. Marchetti, J. Entenza, and J. Bille. 2003. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48:959-976.
22. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmary, B. De Pauw, and F. Meunier. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1979.
23. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
24. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
25. Yeates, C. 2003. DB-289 Immtech International. IDrugs 6:1086-1093.